The indications for treatment with anti-VEGF injection included wet age-related macular degeneration (34 patients, 81%), diabetic macular edema (6 patients, 14%), proliferative diabetic retinopathy (1 patient, 2%), and branch retinal vein occlusion (1 patient, 2%). Here, VEGFA is linked to wet macular degeneration.